<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811485</url>
  </required_header>
  <id_info>
    <org_study_id>CLMF237A1303</org_study_id>
    <nct_id>NCT01811485</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy</brief_title>
  <acronym>CLMF237A1303</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the efficacy and safety of LMF237 50/250 mg and
      50/500 mg bid in Japanese patients with T2DM inadequately controlled with vildagliptin
      monotherapy. This study was conducted to support registration of the fixed-dose combination
      of vildagliptin and metformin for the treatment of T2DM in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
    <description>HbA1c was performed on a blood sample obtained and measured by High performance liquid chromatography (HPLC). HPCL was performed at a central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at 14 Weeks Within LMF237 Treatment Groups</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
    <description>HbA1c will be performed on a blood sample obtained and measured by HPLC. HPCL was performed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Meeting Responder Rates in HbA1c</measure>
    <time_frame>Baseline, 14 weeks</time_frame>
    <description>Responder rate was analyzed in categories: 1. Endpoint HbA1c ≤ 6.5% 2. Endpoint HbA1c &lt; 7% 3. Endpoint HbA1c &lt; 7% in patients with baseline HbA1c ≤ 8% 4. Endpoint HbA1c &lt; 6.9% 5. HbA1c reduction from baseline at endpoint ≥ 1% 6. HbA1c reduction from baseline at endpoint ≥ 0.5%.
Categories 1, 2, and 4 - 'n' includes only patients with baseline HbA1c &gt; 6.5%, ≥ 7%, ≥ 6.9% and endpoint HbA1c measurement. Category 3, 'n' includes only patients with 7% ≤ baseline HbA1c ≤ 8% and endpoint HbA1c. Category 5 and 6, 'n' indicates number of patients with both baseline and endpoint HbA1c measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at 14 Weeks</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
    <description>FPG was performed on a blood sample obtained and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death</measure>
    <time_frame>14 weeks</time_frame>
    <description>The occurrence of adverse events were sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LMF237 50/250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMF237 50/500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMF237 50/250 mg</intervention_name>
    <description>Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily</description>
    <arm_group_label>LMF237 50/250 mg</arm_group_label>
    <arm_group_label>LMF237 50/500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMF237 50/500 mg</intervention_name>
    <description>Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily</description>
    <arm_group_label>LMF237 50/250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes inadequately controlled with diet, exercise and oral
             anti-diabetic therapy

          -  HbA1c in the range of 7.0-10.0%

          -  Body mass index in the range of 20-35 kg/m^2

        Exclusion Criteria:

          -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or
             secondary forms of diabetes

          -  Significant heart diseases Other protocol-defined inclusion/exclusion criteria may
             apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuoka</state>
        <zip>818-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>819-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>807-0857</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koga-city</city>
        <state>Ibaraki</state>
        <zip>306-0232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>221-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yatsushiro-city</city>
        <state>Kumamoto</state>
        <zip>866-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yatsushiro-city</city>
        <state>Kumamoto</state>
        <zip>866-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakai-city</city>
        <state>Osaka</state>
        <zip>590-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki-city</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ageo-city</city>
        <state>Saitama</state>
        <zip>362-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa-city</city>
        <state>Saitama</state>
        <zip>359-1161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>134-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>177-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <results_first_submitted>February 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LMF237 50/250 mg</title>
          <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
        </group>
        <group group_id="P2">
          <title>LMF237 50/500 mg</title>
          <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56">&quot;Started&quot; indicates randomized patients</participants>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set</population>
      <group_list>
        <group group_id="B1">
          <title>LMF237 50/250 mg</title>
          <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
        </group>
        <group group_id="B2">
          <title>LMF237 50/500 mg</title>
          <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="11.24"/>
                    <measurement group_id="B2" value="58.3" spread="10.50"/>
                    <measurement group_id="B3" value="56.2" spread="9.75"/>
                    <measurement group_id="B4" value="57.0" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups</title>
        <description>HbA1c was performed on a blood sample obtained and measured by High performance liquid chromatography (HPLC). HPCL was performed at a central laboratory.</description>
        <time_frame>Baseline to 14 weeks</time_frame>
        <population>Full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled LMF237</title>
            <description>All patients who took LMF237 50/250 mg or LMF237 50/500 mg twice daily for 14 weeks were pooled together as reporting group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups</title>
          <description>HbA1c was performed on a blood sample obtained and measured by High performance liquid chromatography (HPLC). HPCL was performed at a central laboratory.</description>
          <population>Full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="0.14" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at 14 Weeks Within LMF237 Treatment Groups</title>
        <description>HbA1c will be performed on a blood sample obtained and measured by HPLC. HPCL was performed at a central laboratory.</description>
        <time_frame>Baseline to 14 weeks</time_frame>
        <population>Full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>LMF237 50/250 mg</title>
            <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>LMF237 50/500 mg</title>
            <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at 14 Weeks Within LMF237 Treatment Groups</title>
          <description>HbA1c will be performed on a blood sample obtained and measured by HPLC. HPCL was performed at a central laboratory.</description>
          <population>Full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.06"/>
                    <measurement group_id="O2" value="-1.04" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Meeting Responder Rates in HbA1c</title>
        <description>Responder rate was analyzed in categories: 1. Endpoint HbA1c ≤ 6.5% 2. Endpoint HbA1c &lt; 7% 3. Endpoint HbA1c &lt; 7% in patients with baseline HbA1c ≤ 8% 4. Endpoint HbA1c &lt; 6.9% 5. HbA1c reduction from baseline at endpoint ≥ 1% 6. HbA1c reduction from baseline at endpoint ≥ 0.5%.
Categories 1, 2, and 4 - 'n' includes only patients with baseline HbA1c &gt; 6.5%, ≥ 7%, ≥ 6.9% and endpoint HbA1c measurement. Category 3, 'n' includes only patients with 7% ≤ baseline HbA1c ≤ 8% and endpoint HbA1c. Category 5 and 6, 'n' indicates number of patients with both baseline and endpoint HbA1c measurements.</description>
        <time_frame>Baseline, 14 weeks</time_frame>
        <population>The full analysis set (FAS) consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled LMF237</title>
            <description>All patients who took LMF237 50/250 mg or LMF237 50/500 mg twice daily for 14 weeks were pooled together as reporting group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Meeting Responder Rates in HbA1c</title>
          <description>Responder rate was analyzed in categories: 1. Endpoint HbA1c ≤ 6.5% 2. Endpoint HbA1c &lt; 7% 3. Endpoint HbA1c &lt; 7% in patients with baseline HbA1c ≤ 8% 4. Endpoint HbA1c &lt; 6.9% 5. HbA1c reduction from baseline at endpoint ≥ 1% 6. HbA1c reduction from baseline at endpoint ≥ 0.5%.
Categories 1, 2, and 4 - 'n' includes only patients with baseline HbA1c &gt; 6.5%, ≥ 7%, ≥ 6.9% and endpoint HbA1c measurement. Category 3, 'n' includes only patients with 7% ≤ baseline HbA1c ≤ 8% and endpoint HbA1c. Category 5 and 6, 'n' indicates number of patients with both baseline and endpoint HbA1c measurements.</description>
          <population>The full analysis set (FAS) consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c ≤ 6.5% (n=115, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt; 7.0% (n= 107, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt; 7.0% with baseline HbA1c ≤ 8.0% (n=69,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt; 6.9% (n= 111, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of HbA1c ≥ 1% (n= 115, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of HbA1c ≥ 0.5% (n= 115, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 14 Weeks</title>
        <description>FPG was performed on a blood sample obtained and analyzed at a central laboratory.</description>
        <time_frame>Baseline to 14 weeks</time_frame>
        <population>FAS consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled LMF237</title>
            <description>All patients who took LMF237 50/250 mg or LMF237 50/500 mg twice daily for 14 weeks were pooled together as reporting group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 14 Weeks</title>
          <description>FPG was performed on a blood sample obtained and analyzed at a central laboratory.</description>
          <population>FAS consisted of all randomized patients who received at least one dose of study medication and had at least one post-randomization efficacy parameter measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.02" spread="2.83"/>
                    <measurement group_id="O2" value="16.54" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death</title>
        <description>The occurrence of adverse events were sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
        <time_frame>14 weeks</time_frame>
        <population>Safety set (SAF): consists of all patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>LMF237 50/250 mg</title>
            <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>LMF237 50/500 mg</title>
            <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death</title>
          <description>The occurrence of adverse events were sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.</description>
          <population>Safety set (SAF): consists of all patients who received at least one dose of study medication.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (Serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set (SAF): The SAF consists of all patients who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>POOLED LMF237</title>
          <description>All patients who has received LMF237</description>
        </group>
        <group group_id="E2">
          <title>LMF237 50/250mg</title>
          <description>Patients took LMF237 50/250 mg twice daily for 14 weeks</description>
        </group>
        <group group_id="E3">
          <title>LMF237 50/500mg</title>
          <description>Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

